Key result
Adjunctive atorvastatin alters ~240 endothelial genes, inducing NOS3 and KLF4 while suppressing TGFB2 and DKK1.
Why the study?
Damage to coronary arteries during acute Kawasaki disease involves endothelial cell dysfunction, but the response of endothelial cells to Kawasaki disease treatment was not understood.
Does atorvastatin treatment alter the transcriptional profile of endothelial cells exposed to Kawasaki disease sera to promote homeostasis and reduce inflammation?
Observational (n=10)
No
Does atorvastatin treatment alter the transcriptional profile of endothelial cells exposed to Kawasaki disease sera to promote homeostasis and reduce inflammation?
Atorvastatin treatment in acute Kawasaki disease may improve endothelial cell health and reduce inflammation by modulating specific gene expression pathways.
Answers are grounded in this paper and cite their sources.
Atorvastatin alters endothelial transcripts in Kawasaki models; hypothesis-generating and should not yet change practice.
Background Damage to the coronary arteries during the acute phase of Kawasaki disease (KD) is linked to inflammatory cell infiltration, myointimal proliferation, and endothelial cell (EC) dysfunction. To understand the response of ECs to KD treatment, we studied the genome‐wide transcriptional changes in cultured ECs incubated with KD sera before and after treatment with or without atorvastatin. Methods and Results RNA sequencing of human umbilical vein ECs incubated with pooled sera from patients with acute KD before or after treatment with intravenous immunoglobulin and infliximab revealed differentially expressed genes in interleukin‐1, tumor necrosis factor‐α, and inflammatory cell recruitment pathways. Subacute sera pooled from patients treated with intravenous immunoglobulin, infliximab, and atorvastatin uniquely induced expression of NOS3 , Kruppel like factor ( KLF2 , and KLF4 (promotes EC homeostasis and angiogenesis) and ZFP36 ring finger protein (ZFP36) and suppressor of cytokine signaling 3 (SOCS3) (suppresses inflammation), and suppressed expression of TGFB2 and DKK1 (induces endothelial‐mesenchymal transition) and sphingosine kinase 1 (SPHK1) and C‐X‐C motif chemokine ligand 8 (CXCL8) (induces inflammation). Conclusions These results suggest that atorvastatin treatment of patients with acute KD may improve EC health, reduce mediators of inflammation produced by ECs, and block KD‐induced myofibroblast proliferation.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2022) conducted an observational in Acute Kawasaki Disease (n=10). Atorvastatin added to intravenous immunoglobulin (IVIG) and infliximab vs. Intravenous immunoglobulin (IVIG, 2 g/kg) and infliximab (5-10 mg/kg) without atorvastatin was evaluated on Differentially expressed genes (DEGs) in cultured human umbilical vein endothelial cells (HUVECs) incubated with subacute post-treatment patient sera (p=<0.0001). Atorvastatin added to IVIG and infliximab altered 240 endothelial genes, inducing NOS3/KLF4 and suppressing TGFB2/DKK1.
Synapse has enriched 10 related papers. Consider them for comparative context: